Edgewise Therapeutics

Check out our video talking about why we are leaders in muscle disease science. We're excited to be part of the Biophysical Society's 60th Annual Meeting. Link to the full video here: ?https://lnkd.in/ejD8KDQE

Join us at the #MDAConference in Dallas, Texas! See Prof. Craig McDonald's presentation, "CANYON trial results: Sevasemten, an investigational fast skeletal myosin inhibitor, reduced muscle damage biomarkers and stabilized function in BMD" on March 19 at 10:30am CST. Our team will also be presenting five scientific posters on #BeckerMuscularDystrophy We look forward to connecting with you and hearing the latest on muscle research, science and clinical advancements. See you there! Read our press release to learn more: https://lnkd.in/exZAg46r

This #InternationalWomensDay, we applaud the incredible women at Edgewise who are playing a role in advancing a new era of muscle-focused therapeutics for patients and families impacted by serious muscle diseases. Here's to all women paving the path toward a stronger future!

This #InternationalWomensDay, we applaud the incredible women at Edgewise who are playing a role in advancing a new era of muscle-focused therapeutics for patients and families impacted by serious muscle diseases. Here's to all women paving the path toward a stronger future!

We had a wonderful time in Italy with our friends at Parent Project aps attending their 20th International Conference on Duchenne and Becker Muscular Dystrophy. Our VP, Patient Advocacy & External Innovation, Abby Bronson attended the annual event, "Parent Project Italy was a valuable and interactive conference, for the entire Becker and Duchenne community, to hear from experts on the latest research, care and community building. The Becker round table discussion was especially educational and empowering, giving this disease and the Becker community a chance for their voices to be heard." #Duchenne #BeckerMuscularDystrophy

What an incredible evening! Members of our Colorado team had the honor of attending the American Heart Association's Heart Ball to celebrate the progress and advancements in heart health. Engaging with our peers and the community will empower us to foster and support the patients and families we serve at Edgewise. It's an honor to do our part and be leaders in the conversation! #HCM #HCMAwareness

We are excited to announce the completion– and over enrollment of– our GRAND CANYON cohort of sevasemten in Becker muscular dystrophy. “We are committed to advancing sevasemten urgently as we move towards our goal of bringing the first treatment option to individuals living with Becker.” - Joanne Donovan, Ph.D., M.D., Chief Medical Officer, Edgewise Therapeutics #Becker #BeckerMD #BeckerMuscularDystrophy

Edgewise management will be presenting at the Leerink Partners Global Healthcare Conference. Join our President and CEO Kevin Koch, Ph.D. and Chief Operating Officer, Behrad Derakhshan, PhD for a fireside chat on March 11 at 1:40pm ET. See our press release for more details: https://lnkd.in/exZAg46r

Today we announced Q4 2024 financial results and recent business highlights. The results are available on our website: https://bit.ly/4dosM6r

As we observe Rare Disease Day, Edgewise wants to acknowledge all of the individuals and advocacy organizations in the rare disease community who continually push forward efforts to advance research and improve millions of lives around the world. Edgewise is grateful to work in the rare disease space with such a remarkable community. #RareDiseaseDay